These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 26202742)

  • 21. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.
    Mortensen MB
    Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.
    Krajewski KM; Fougeray R; Bellmunt J; Pons F; Schutz FA; Rosenberg JE; Salhi Y; Choueiri TK
    Eur J Cancer; 2012 Jul; 48(10):1495-502. PubMed ID: 22176867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI volume measurements compared with the RECIST 1.1 for evaluating the response to neoadjuvant chemotherapy for mass-type lesions.
    An YY; Kim SH; Kang BJ; Lee AW; Song BJ
    Breast Cancer; 2014 May; 21(3):316-24. PubMed ID: 22767314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas.
    Shah GD; Kesari S; Xu R; Batchelor TT; O'Neill AM; Hochberg FH; Levy B; Bradshaw J; Wen PY
    Neuro Oncol; 2006 Jan; 8(1):38-46. PubMed ID: 16443946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of unidimensional and bidimensional measurement to assess therapeutic response in the treatment of solid tumors].
    Hauth EA; Stattaus J; Forsting M
    Radiologe; 2007 Jul; 47(7):628, 630-4. PubMed ID: 16440191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement.
    Schwartz LH; Mazumdar M; Brown W; Smith A; Panicek DM
    Clin Cancer Res; 2003 Oct; 9(12):4318-23. PubMed ID: 14555501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
    Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
    Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [RECIST and the radiologist].
    Cervera Deval J
    Radiologia; 2014; 56(3):193-205. PubMed ID: 22902252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review.
    Kim JH
    Oncotarget; 2016 Mar; 7(12):13680-7. PubMed ID: 26885610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. QA procedures for multimodality preclinical tumor drug response testing.
    Lee YC; Goins BA; Fullerton GD
    Med Phys; 2010 Sep; 37(9):4806-16. PubMed ID: 20964200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging.
    Buijs M; Kamel IR; Vossen JA; Georgiades CS; Hong K; Geschwind JF
    J Vasc Interv Radiol; 2007 Aug; 18(8):957-63. PubMed ID: 17675611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The minimum number of target lesions that need to be measured to be representative of the total number of target lesions (according to RECIST).
    Darkeh MH; Suzuki C; Torkzad MR
    Br J Radiol; 2009 Aug; 82(980):681-6. PubMed ID: 19366735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim TH; Kang DK; Yim H; Jung YS; Kim KS; Kang SY
    J Comput Assist Tomogr; 2012; 36(2):200-6. PubMed ID: 22446360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
    Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal lesion number for evaluation of tumor response in response evaluation criteria in solid tumors.
    Rosen MA; Sullivan D
    J Clin Oncol; 2010 Apr; 28(10):e159-60; author reply e161. PubMed ID: 20159810
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.
    Kim JH; Kim BJ; Jang HJ; Kim HS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):729-735. PubMed ID: 28780726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.
    Seyal AR; Gonzalez-Guindalini FD; Arslanoglu A; Harmath CB; Lewandowski RJ; Salem R; Yaghmai V
    Hepatology; 2015 Oct; 62(4):1111-21. PubMed ID: 25999236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Measurement of tumour response to cancer treatment: morphologic imaging role].
    Ollivier L; Leclère J; Thiesse P; Di Stefano D; Vincent C
    Bull Cancer; 2007 Feb; 94(2):171-7. PubMed ID: 17337386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.